Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,844

Fighter pilots and brain surgeons have a lot in common. With limited time and a high degree of risk, they must zero in on a dangerous target with the intent to destroy, making sure to minimise any collateral damage.

Perhaps no one understands that relationship better than Alon Geri and Moty Avisar, veterans of the Israeli Air Force and co-founders of Surgical Theatre, an Ohio-based company that brings state-of-the-art virtual reality to brain surgeons.

Physicians in thick black goggles can step inside a patient’s skull, explore the malformed region, craft a strategy for entry, elimination, and exit, and even do dry runs of the surgery itself. When it comes time to make the first incision, there are fewer surprises.

Read more

Technology is amazing and can be used to help so many. When I position technology; I do so in showing how it helps folks to combat devastating diseases, live life fully even if they became paralyzed at some point in their life and with technology they can walk again, etc. I caution folks to ensure that when we introduce technology that we explain our message well to the broader masses; or risk not be adopted.

We have to do a better job in explaining how AI, BMI, etc. will help the population. When we present things like BMI, Cell Circuitry, etc. we must market how folks used the technology to combat a disease, a disability, or be able to live a more fuller life, etc. I keep seeing either no message or the wrong message being presented to the masses. Instead of waiting for the technology being available; we must take consumers on a journey of possibilities that they can have with tech.

Most Americans are put off by the idea of using science to “enhance” human abilities — and these attitudes are strongly connected with people’s religiosity.

That’s according to a new Pew Research Center survey, which looked at public attitudes about human enhancement technologies.

We may all want to be sharp, strong and healthy but, as the survey found, most people are worried about the use of emerging biomedical technologies that seek to push the boundaries of human capacities.

Continue reading “Religion plays a role in attitudes toward human enhancement technologies” | >

Southern US is having a bad summer. Zika in FL and Brain eating amoebas in SC.

CHARLESTON COUNTY, S.C. — A patient in South Carolina has tested positive for Naegleria fowleri, the so-called “brain-eating amoeba,” The Centers for Disease Control confirmed in a statement.

Health officials think the patient may have been exposed during a July 24 swim at Martin’s Landing in the Edisto River, which runs through the southeast portion of the state through the Ernest F. Hollings Ace Basin National Wildlife park.

The amoeba occurs naturally and is “all around us and is present in many warm water lakes, rivers and streams, but infection in humans is very rare,” Linda Bell, M.D. and state epidemiologist told WISTV.

Read more

The findings showed that the shrinking of the hippocampus — brain region associated with learning and memory — actually precedes the onset of a change in behaviour — namely the loss of memory. “Until now, no one knew the evolution of these changes. Does the hippocampus shrink before or after memory loss? Or do the two happen handin- hand,” said Sumantra Chattarji, Professor at National Centre for Biological Sciences in Bengaluru, Karnataka, in a statement.

Using rats as a model system which reacts to stress much as humans do, the team studied how the brain changes in structure during stress. The results showed that when under stress, rats develop anxiety-related behaviours and their ability to form memories are affected. In the study, rats were subjected to stress for two hours every day over 10 days. The brains were examined with MRI scans on several days over the course of the study, and their ability to form memories were assessed repeatedly.

After just three days of stress, the hippocampus of every stressed rat had shrunk. “Normally structural changes are seen in the brain after a long time — say 10 to 20 days. Three days doesn’t even count as chronic stress,” Chattarji added. Five days after stress exposure, the rats’ hippocampus-based ability to make memories was tested again. The stressed rats were found to perform almost as well as unstressed rats, the researchers said. “Volume loss and shrinkage has happened, yet spatial memory is still holding up,” Chattarji said.

Read more

I see many uses for this such as provider services including front office & hospital admissions, security in assessing people in line or trying to gain entry, etc.

Machines are taking over more and more tasks. Ideally, they should also be capable to support the human in case of poor performance. To intervene appropriately, the machine should understand what is going on with the human. Fraunhofer scientists have developed a diagnostic tool that recognizes user states in real time and communicates them to the machine.

The camera firmly focuses on the driver’s eyes. If they are closed for more than one second, an alarm is triggered. This technique prevents the dangerous micro-sleep at the wheel. “It is not always as easy for a machine to detect what state the human is in, as it is in this case,” says Jessica Schwarz from the Fraunhofer Institute for Communication, Information Processing and Ergonomics FKIE in Wachtberg, just south of Bonn.

Holistic model feeds real-time diagnosis

For her doctoral thesis, the graduate psychologist examined the question of how to very precisely determine user states, what influence these may have on incorrect behavior and how automated systems can use this information. “For complex applications it is not sufficient to focus on only one impact factor,” says the scientist. An increased heart rate, for example, does not automatically mean that a person is stressed. This can have various causes. Schwarz therefore examined what factors specifically impact human performance and created a holistic model that provides a detailed view on user states and their causes.

Read more

Big Data and 3D.

3D printing remains one of those technological areas that holds a great amount of fascination. What began as a type of niche market has expanded rapidly in the past few years to encompass nearly every industry out there, from the medical field to manufacturing.

The outlook is a positive one in terms of 3D printing’s future, with Gartner predicting the amount of spending on 3D printers to exceed more than $13 billion in 2018. While 3D printing has always held a lot of promise, one of the factors truly taking the concept to the next level is big data.

In much the same way that big data has benefited businesses of all types and sizes, it has proven to play a pivotal role in the growth of 3D printing. As more organizations get a firm grasp on how best to use both big data analytics and 3D printing capabilities, the two areas will form a more established and interdependent relationship.

Read more

Nice.

When we think of synthetic biology, we often think of engineering a cell to give it some useful function. But SEED 2016 had quite a few speakers working outside of a biological cell. Some broke open cells to utilize just the cellular machinery to create “cell-free” systems. Others showed what could be done inside of the computer (in silico) to improve our understanding and prediction of synthetic gene networks. Here, we’re highlighting SEED speakers who showed how both of these approaches can advance synthetic biology.

Cell-free synthetic biology

Roy Bar-Ziv gave the first keynote at SEED 2016. His group at the Weissman Institute has made tremendous progress toward using cell-free expression that can mimic the behavior of real cells. Over the last 12 years they developed their ‘artificial cells’ using microfluidics and DNA arrayed on 2D substrates as DNA brushes. Each spot of DNA can be programmed the same as DNA in cells, and unlike other cell-free expression setups the microfluidics allows for dynamics.

Read more

Listen to famed biogerontolgist Aubrey de Grey explain the OncoSENS approach to curing ALT-Cancer (https://www.lifespan.io/campaigns/sens-control-alt-delete-cancer/) and how this is a vital part of overcoming the ill-effects of aging. This presentation is part of the Designing New Advances conference held by the Institute of Exponential Sciences in the Netherlands.

Read more

Tempus fugit. I’m just about old enough to remember a time in which 2020 was the distant future of science fiction novels, too far away to be thinking about in concrete terms, a foreign and fantastical land in which anything might happen. Several anythings did in fact happen, such as the internet, and the ongoing revolution in biotechnology that has transformed the laboratory world but leaks into clinics only all too slowly. Here we are, however, close enough to be making plans and figuring out what we expect to be doing when the third decade of the 21st century gets underway. The fantastical becomes the mundane. We don’t yet have regeneration of organs and limbs, or therapies to greatly extend life, but for these and many other staples of golden age science fiction, the scientific community has come close enough to be able to talk in detail about the roads to achieving these goals.

Of all the things that researchers might achieve with biotechnology in the near future, control over aging is by far the most important. Aging is the greatest cause of death and suffering in the world, and none of us are getting any younger. That may change, however. SENS, the Strategies for Engineered Negligible Senescence, is a synthesis of the scientific view of aging as an accumulation of specific forms of cell and tissue damage, pulling in a century of evidence from many diverse areas of medical science to support this conclusion. Aging happens because the normal operation of our cellular biochemistry produces damage, wear and tear at the level of molecules and molecular structures, and some of that damage accumulates to cause failure of tissues and organs, and ultimately death.

Read more

Philadelphia, PA, USA / Mexico City, Mexico — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bioproducts for complex regeneration, disease reversion, and aging, and RegenerAge SAPI de CV, (www.regenerage.clinic/en/) a clinical company focused on translational therapeutic applications of a range of regenerative and rejuvenation healthcare interventions, have announced a collaboration to focus on novel combinatorial approaches in human disease and wellness. SGR-Especializada (http://www.sgr-especializada.com/), regulatory experts in the Latin American healthcare market, assisted in the relationship.

regenerage

“We are very excited about this collaboration with RegenerAge SAPI de CV,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular and biologic to applications of regenerative and rejuvenative medicine will make for novel and transformational opportunities in a range of degenerative disorders.”

As we close in on $7 trillion in total annual health care expenditures around the globe ($1 trillion spent on pharmaceutical products; $200 billion on new R&D), we are simultaneously witnessing a paradoxical rise in the prevalence of all chronic degenerative diseases responsible for human suffering and death.

With the emergence of such trends including: personalization of medicine on an “n-of-1” basis, adaptive clinical design, globalization of health care training, compassionate use legislative initiatives for experimental therapies, wider acceptance of complementary medical technologies, and the growth of international medical travel, patients and clinicians are more than ever before, exploring the ability to access the therapies of tomorrow, today.

recovering patient

The estimate of the current market size for procedural medical travel, defined by medical travelers who travel across international borders for the purpose of receiving medical care, is in the range of US $40–55 billion.

Additionally, major clinical trial gaps currently exist across all therapeutic segments that are responsible for human suffering and death. Cancer is one prime example. As a leading cause of morbidity and mortality worldwide for many decades, today there are approximately 14 million new cases diagnosed each year, with over 8 million cancer related deaths annually. It is estimated that less than 5% of these patients, take the initiative to participate in any available clinical studies.

“We look forward to working closely with Bioquark Inc. on this exciting initiative,” said Dr. Joel Osorio, Chief of Clinical Development RegenerAge SAPI de CV. “The ability to merge cellular and biologic approaches represents the next step in achieving comprehensive regeneration and disease reversion events in a range of chronic diseases responsible for human suffering and death.”

bioquarklogo

About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

About RegenerAge SAPI de CV

RegenerAge SAPI de CV is a novel clinical company focused on translational therapeutic applications, as well as expedited, experimental access for “no option” patients, to a novel range of regenerative and reparative biomedical products and services, with the goal of reducing human degeneration, suffering, and death.